Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Integrate Sample Prep Products into Artus Molecular Diagnostics

NEW YORK, Dec. 10 (GenomeWeb News) - Qiagen's German subsidiary has entered into a manufacturing and supply deal with Artus, of Hamburg, Germany in which Artus will integrate Qiagen's nucleic acid sample preparation products into its infectious disease diagnostic systems, the companies said today.

 

Under the agreement, Artus will use versions of Qiagen's QiAamp technology into its custom diagnostic tooks, which include systems for detection of diseases such as SARS, Herpes simplex virus -1/-2, EBV, West Nile Virus, Malaria, and Salmonella. The systems use Artus' RealArt technology, which is based on PCR technology that Artus has licensed from Roche, according to the companies.

 

The companies did not disclose the financial terms of the agreement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.